Levofloxacin Prophylaxis for Autologous Stem Cell Transplant: A Second Look

摘要: Introduction Autologous stem cell transplant patients (ASCT) are at risk for bacterial. Antibacterial prophylactic strategy is variable among centers. Fluoroquinolone prophylaxis in ASCT has not been found to add a survival benefit. We performed retrospective review of undergoing with and without bacterial compare endpoints interest. Methods At our institution, multiple myeloma (MM) receive levofloxacin 500 mg daily as prophylaxis, while lymphoma do not. retrospectively examined MM or between July 2015 2018 bacteremia episodes. received melphalan BEAM. All growth factor support. Clinical microbial data was recorded analyzed using SPSS. Results In total, 172 underwent 343 MM. Seventeen percent (30/172) 5.5% (19/324) had febrile neutropenic episodes associated bacteremia. Relative 3.1 [1.83 – 5.43, p Discussion resulted less blood stream infection but more breakthrough infections resistant isolates. There no statistically significant difference the rates CDI despite trend lower incidence group. Bacteremia difficult treat were two infection-related mortalities era antimicrobial resistance, further reevaluation utility fluoroquinolone should be carefully weighed against risks.